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Recent experimental ﬁndings have shown that basophils may be
highly important in anaphylaxis or IgE-mediated very-late-phase
skin inﬂammation.1 Activation of basophils by immunological stim-
uli is known to be modiﬁed by various exogenous substances hav-
ing anti-allergic properties. Bisphenols appear to have such
properties; several chemicals belonging to bisphenols, including
quercetin and curcumin, are reported to down-regulate activation
of basophils or other allergic effector cells and to suppress allergic
inﬂammation.2 Recently, resveratroldanother bisphenoldhas
attracted researchers' attention since it is included in red wine
and is thought to improve various indices of French peoples' health
status.3 Although resveratrol is suspected to share a variety of anti-
oxidant properties with quercetin, its precise biological actions
have not been fully elucidated.
In this study, we assessed the effect of resveratrol on basophil
activation, detected as release of histamine and leukotriene C4
(LTC4). Basophils were obtained from non-allergic volunteers by
dextran sedimentation of venous blood (purity ~1%). In some ex-
periments, highly puriﬁed basophils prepared by Percoll gradient
centrifugation plus negative MACS selection were used.4 Cells
were preincubated with resveratrol (Wako Pure Chemicals, Osaka,
Japan) for 30 min at 37 C, washed and then stimulated with secre-
tagogues for 45 min4 Histamine and LTC4 in the supernatant were
measured using an autoanalyzer and ELISA kits (Cayman Chemical,
Ann Arbor, MI, USA), respectively.
Histamine release from basophils in response to treatment
with each of polyclonal anti-IgE antibody (MBL, Nagoya, Japan),
phorbol myristate acetate (PMA) (Sigma, St. Louis, MO, USA) and
calcium ionophore A23187 (Sigma) was signiﬁcantly suppressed
by preincubation of the cells for 30 min with resveratrol at 30 or
100 mM (Fig. 1a). Similar results were obtained for highly puriﬁed
basophils (purity > 80%), suggesting that resveratrol acts directly
on basophils (Fig. 1b). Resveratrol did not cause apparent damage
to basophils, since basophil preparations pretreated with this sub-
stance at 100 mM for 2 h had a normal histamine content and
showed histamine releasability similar to that of 30-min-pre-
treated basophils (data not shown). In the next experiments,
dextran-sedimented basophils were pretreated with serial con-
centrations of resveratrol for 30 min and a basophil-priming cyto-
kine, IL-3, for 15 min before stimulation with anti-IgE antibody
(Fig. 1c). Resveratrol signiﬁcantly down-regulated histaminePeer review under responsibility of Japanese Society of Allergology.
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licenses/by-nc-nd/4.0/).release from basophils treated with all the tested concentrations
of IL-3. Next, the effect of resveratrol on basophil LTC4 release
was assessed (Fig. 1d). Basophils stimulated with anti-IgE anti-
body released LTC4, and this was augmented by pretreatment
with IL-3. Resveratrol at 100 mM strongly suppressed LTC4 secre-
tion from anti-IgE-antibody-stimulated basophils. Lastly, baso-
phils were pretreated with resveratrol or quercetin, washed and
stimulated with anti-IgE antibody (Fig. 1e). Quercetin at 100 mM
signiﬁcantly suppressed histamine release, and the effect of quer-
cetin was slightly more potent than that of resveratrol.
Our results clearly indicate that resveratrol down-regulates
basophil mediator release induced by IgE-mediated and non-IgE-
mediated stimulation. These ﬁndings are in line with previous re-
ports showing that this substance suppresses activation of rodent
mast cells and human eosinophils at concentrations similar to
those used in the present study.5,6 Resveratrol can thus be regarded
as negative regulators of allergic inﬂammatory cell activation. It
will be interesting to assess whether, and to what extent, dietary
supplementation of resveratrol affects our immunological status.7
The serum concentration of resveratrol (~10 mM) is close to the
effective dose in our study, suggesting that modulation of basophil
functions might also take place in vivo.
Various activities of resveratrol are being unveiled through
recent experimental approaches. Rodent studies demonstrated
that this compound is able to suppress allergic reactions in the air-
ways.8e10 Resveratrol can also suppress tissue-damaging or stress-
related responses via anti-oxidant or other signal-modifying mech-
anisms.3 Various in vivo studies found that resveratrol exerts organ-
protective effects. In addition, the broad action of this compound
improves the outcome of diabetes mellitus and cancer.3 We sur-
mise that allergic diseases may also be important targets of resver-
atrol. Although the in vivo signiﬁcance of our ﬁndings and the
overall import of the immunological actions of resveratrol remain
unclear, elucidation of the precise roles of this unique compound
in various allergic disorders is strongly warranted.
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Fig. 1. Modulation of basophil mediator release by resveratrol. (a) Basophil preparations were preincubated with and without various concentrations of resveratrol for 30 min at
37 C and then stimulated with secretagogues for 45 min. Histamine release was expressed as a percentage of the total cellular histamine after subtracting spontaneous release
(usually < 5%). Data are the mean ± SEM of four separate experiments. *p < 0.05, versus corresponding values of cells not preincubated with resveratrol, assessed by one-way
ANOVA followed by Tukey post-hoc test. (b) Resveratrol at 100 mM affects histamine release from highly puriﬁed basophils. Data are the mean ± SEM (n ¼ 4). *p < 0.05, versus
corresponding cells not preincubated with resveratrol. (c) Effects of resveratrol and IL-3 on basophil degranulation. Cells were preincubated with and without resveratrol at
100 mM for 30 min, washed and then incubated with and without IL-3 for 15 min before stimulation with anti-IgE antibody at 1.4 mg/ml. Data are the mean ± SEM (n ¼ 3).
*p < 0.05, versus the corresponding value of cells not preincubated with resveratrol. (d) Effect of resveratrol on basophil LTC4 release. Data are the mean ± SEM (n ¼ 3).
*p < 0.05, versus the corresponding value of cells not preincubated with resveratrol. (e) Stock solutions were prepared and stored at 80 C for resveratrol at 50 mM in ethanol
and quercetin at 50 mM in DMSO. Basophils were preincubated with and without diluted resveratrol or quercetin for 30 min at 37 C, washed and then stimulated with anti-IgE
antibody for 45 min. Percentages of histamine release by cells preincubated with vehicle are also shown. Data are the mean ± SEM (n ¼ 4). *p < 0.05, versus the corresponding value
of vehicle-pretreated cells. Res: resveratrol; Quer: quercetin.
Letter to the Editor / Allergology International 64 (2015) S80eS82 S81
Letter to the Editor / Allergology International 64 (2015) S80eS82S82Yusuke Tanaka a, Masao Yamaguchi a,*, Maho Suzukawa b,
Hidenori Arai a, Hiroyuki Nagase a, Ken Ohta a,b
a Division of Respiratory Medicine and Allergology, Department of Medicine, Teikyo
University School of Medicine, Tokyo, Japan
b National Hospital Organization Tokyo National Hospital, Tokyo, Japan
* Corresponding author. Division of Respiratory Medicine and Allergology,
Department of Medicine, Teikyo University School of Medicine, 2-11-1 Kaga,
Itabashi-ku, Tokyo 173-8605, Japan.
E-mail address: myama@med.teikyo-u.ac.jp (M. Yamaguchi).References
1. Karasuyama H, Mukai K, Obata K, Tsujimura Y, Wada T. Nonredundant roles of
basophils in immunity. Annu Rev Immunol 2011;29:45e69.
2. Hayashi Y, Matsushima M, Nakamura T, Shibasaki M, Hashimoto N, Imaizumi K,
et al. Quercetin protects against pulmonary oxidant stress via heme oxygenase-
1 induction in lung epithelial cells. Biochem Biophys Res Commun 2012;417:
169e74.
3. Ichikawa T, Hayashi R, Suzuki K, Imanishi S, Kambara K, Okazawa S, et al. Sir-
tuin 1 activator SRT1720 suppresses inﬂammation in an ovalbumin-induced
mouse model of asthma. Respirology 2013;18:332e9.4. Koketsu R, Yamaguchi M, Suzukawa M, Tanaka Y, Tashimo H, Arai H, et al. Pre-
treatment with low levels of FcεRI-crosslinking stimulation enhances basophil
mediator release. Int Arch Allergy Immunol 2013;161:S23e31.
5. Tan Y, Lim LH. trans-Resveratrol, an extract of red wine, inhibits human eosin-
ophil activation and degranulation. Br J Pharmacol 2008;155:995e1004.
6. Han SY, Bae JY, Park SH, Kim YH, Park JH, Kang YH. Resveratrol inhibits IgE-
mediated basophilic mast cell degranulation and passive cutaneous anaphy-
laxis in mice. J Nutr 2013;143:632e9.
7. Okada Y, Oh-oka K, Nakamura Y, Ishimaru K, Matsuoka S, Okumura K, et al. Di-
etary resveratrol prevents the development of food allergy in mice. PLoS One
2012;7:e44338.
8. Lee M, Kim S, Kwon OK, Oh SR, Lee HK, Ahn K. Anti-inﬂammatory and anti-
asthmatic effects of resveratrol, a polyphenolic stilbene, in a mouse model of
allergic asthma. Int Immunopharmacol 2009;9:418e24.
9. Royce SG, Dang W, Yuan G, Tran J, El Osta A, Karagiannis TC, et al. Resveratrol
has protective effects against airway remodeling and airway hyperreactivity in
a murine of allergic airways disease. Pathobiol Aging Age Relat Dis 2011;1:7134.
10. Aich J, Mabalirajan U, Ahmad T, Khanna K, Rehman R, Agrawal A, et al. Resver-
atrol attenuates experimental allergic in mice by restoring inositol polyphos-
phate 4 phosphatase (INPP4A). Int Immunopharmacol 2012;14:438e43.
Received 17 December 2014
Received in revised form 26 April 2015
Accepted 7 May 2015
Available online 6 June 2015
